• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Society for Medical Oncology (ESMO) Asia

December 06 - 08, 2024

  1. Durvalumab
  2. Durvalumab + Tremelimumab
  3. Trastuzumab Deruxtecan

ppt

Safety of 30 min infusion of durvalumab in combination with gemcitabine-based chemotherapy in first-line treatment of advanced biliary tract cancer: TOURMALINE early results

pdf

Impact of baseline tumour burden on outcomes in EMERALD-1: A phase 3 study of durvalumab ± bevacizumab with transarterial chemoembolisation in embolisation-eligible unresectable hepatocellular carcinoma

pdf

PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT),

ppt

Five-year overall survival and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

ppt

Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric06 final analysis

pdf

Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric06 final analysis [Plain languagae summary]

pdf

Randomized, open-label, multicenter, Phase 3 study of trastuzumab deruxtecan and rilvegostomig vs standard of care in first-line, HER2-expressing, locally advanced or metastatic biliary tract cancer: DESTINY-BTC01

pdf

An open-label, multicenter, phase 2 study of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: DESTINY PanTumor02 part 2

pdf

A Phase 1b/2 open-label study evaluating trastuzumab deruxtecan in combination with rilvegostomig and chemotherapy in patients with HER2+ and HER2-low gastric cancers: DESTINY-Gastric03 Part 4

pdf

Real-world treatment patterns in patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinomain East Asia

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice